Free Trial

Aura Biosciences (AURA) Competitors

Aura Biosciences logo
$6.18 -0.46 (-6.93%)
Closing price 04:00 PM Eastern
Extended Trading
$6.18 0.00 (0.00%)
As of 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AURA vs. CDTX, PAHC, ARDX, TWST, VERA, AVDL, COGT, SNDX, JANX, and SDGR

Should you be buying Aura Biosciences stock or one of its competitors? The main competitors of Aura Biosciences include Cidara Therapeutics (CDTX), Phibro Animal Health (PAHC), Ardelyx (ARDX), Twist Bioscience (TWST), Vera Therapeutics (VERA), Avadel Pharmaceuticals (AVDL), Cogent Biosciences (COGT), Syndax Pharmaceuticals (SNDX), Janux Therapeutics (JANX), and Schrodinger (SDGR). These companies are all part of the "pharmaceutical products" industry.

Aura Biosciences vs. Its Competitors

Cidara Therapeutics (NASDAQ:CDTX) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Cidara Therapeutics currently has a consensus target price of $64.14, suggesting a potential downside of 2.25%. Aura Biosciences has a consensus target price of $22.00, suggesting a potential upside of 255.99%. Given Aura Biosciences' higher possible upside, analysts plainly believe Aura Biosciences is more favorable than Cidara Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cidara Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11
Aura Biosciences
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.11

Aura Biosciences has lower revenue, but higher earnings than Cidara Therapeutics. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cidara Therapeutics$1.27M1,310.33-$169.83M-$11.13-5.90
Aura BiosciencesN/AN/A-$86.92M-$1.96-3.15

Cidara Therapeutics has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Aura Biosciences has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.

In the previous week, Cidara Therapeutics had 3 more articles in the media than Aura Biosciences. MarketBeat recorded 7 mentions for Cidara Therapeutics and 4 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.59 beat Cidara Therapeutics' score of 1.44 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cidara Therapeutics
5 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aura Biosciences
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

35.8% of Cidara Therapeutics shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 3.9% of Cidara Therapeutics shares are held by insiders. Comparatively, 6.3% of Aura Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cidara Therapeutics' return on equity of -50.81% beat Aura Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cidara TherapeuticsN/A -50.81% -42.46%
Aura Biosciences N/A -64.44%-54.24%

Summary

Aura Biosciences beats Cidara Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Aura Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AURA vs. The Competition

MetricAura BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$412.48M$3.12B$5.79B$10.15B
Dividend YieldN/A2.32%5.69%4.61%
P/E RatioN/A21.3074.5925.92
Price / SalesN/A240.30449.5483.33
Price / CashN/A45.3337.0859.91
Price / Book2.039.6112.156.29
Net Income-$86.92M-$53.29M$3.28B$270.85M
7 Day Performance-4.63%0.29%0.98%3.36%
1 Month Performance-10.95%8.91%7.20%6.41%
1 Year Performance-36.87%13.14%63.06%28.26%

Aura Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AURA
Aura Biosciences
2.2575 of 5 stars
$6.18
-6.9%
$22.00
+256.0%
-26.8%$412.48MN/A0.0050Positive News
CDTX
Cidara Therapeutics
3.2774 of 5 stars
$62.15
-1.6%
$64.14
+3.2%
+458.3%$1.60B$1.27M-5.5890Positive News
PAHC
Phibro Animal Health
4.5228 of 5 stars
$39.43
-0.1%
$28.40
-28.0%
+101.4%$1.60B$1.30B33.422,475Trending News
Insider Trade
Analyst Revision
ARDX
Ardelyx
4.6206 of 5 stars
$6.59
+1.1%
$11.70
+77.5%
+12.1%$1.57B$333.61M-28.6590Positive News
TWST
Twist Bioscience
3.978 of 5 stars
$26.25
+1.9%
$49.40
+88.2%
-42.3%$1.55B$312.97M-18.10990News Coverage
VERA
Vera Therapeutics
2.8554 of 5 stars
$24.75
+2.3%
$63.00
+154.5%
-34.7%$1.54BN/A-6.9140Positive News
AVDL
Avadel Pharmaceuticals
2.8913 of 5 stars
$15.38
-2.4%
$20.86
+35.6%
+16.2%$1.53B$221.08M-512.6770
COGT
Cogent Biosciences
2.8699 of 5 stars
$12.68
-2.8%
$20.00
+57.7%
+19.6%$1.49BN/A-7.1280Positive News
SNDX
Syndax Pharmaceuticals
3.9154 of 5 stars
$16.33
-4.2%
$38.89
+138.1%
-10.6%$1.47B$23.68M-4.20110Analyst Forecast
JANX
Janux Therapeutics
2.4885 of 5 stars
$24.81
+3.5%
$85.55
+244.8%
-42.5%$1.44B$10.59M-13.7830News Coverage
Analyst Forecast
SDGR
Schrodinger
3.3844 of 5 stars
$19.44
+1.6%
$27.83
+43.2%
-8.7%$1.41B$207.54M-7.84790

Related Companies and Tools


This page (NASDAQ:AURA) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners